Physician profile
Ashley Derrick
NPI 1831743806
$1,517.49
in general payments reported to CMS, 2019-2025
14 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $206 · 2023: $151 · 2024: $408 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $396.39 | 2024-2025 | Apligraf |
| Leo Pharma INC. | $327.40 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $183.86 | 2021-2025 | |
| Biofrontera INC. | $137.71 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $110.82 | 2021-2022 | |
| Kerecis Limited | $76.67 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Almirall LLC | $76.17 | 2022-2024 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $51.00 | 2021 | |
| Galderma Laboratories, L.P. | $45.81 | 2021-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $34.23 | 2024 | |
| Incyte Corporation | $20.93 | 2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $19.86 | 2021 | |
| Arcutis Biotherapeutics, INC. | $18.85 | 2025 | Zoryve |
| Dermira, INC. | $17.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Derrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.